妊娠期糖尿病(GDM)的药物治疗管理
本文综述妊娠期糖尿病的药物治疗。生活方式干预为初始管理,血糖不达标时启动药物。速效胰岛素类似物门冬胰岛素和赖脯胰岛素较常规胰岛素低血糖更少且胎儿结局相似;长效类似物甘精胰岛素和地特胰岛素与NPH安全性和母婴结局相似。二甲双胍和格列本脲可作替代但存争议,二甲双胍可穿过胎盘且缺乏长期安全性数据,格列本脲可能增加大于胎龄儿和新生儿低血糖风险。
要点
- 生活方式干预是GDM初始管理,血糖不达标时启动药物治疗。
- 速效胰岛素类似物门冬和赖脯胰岛素较常规胰岛素低血糖更少,胎儿结局相似。
- 二甲双胍和格列本脲可作替代但争议大,均穿过胎盘且长期安全性数据缺乏。
核心结论
- 胰岛素仍是GDM生活方式干预不足时改善血糖控制的主要治疗。
- 部分口服降糖药可作GDM替代治疗选择,但许多专业机构仍不将其作为一线治疗。
研究设计与样本
- 本文为综述,概述GDM女性药物治疗及现有治疗方案的已知安全性。
主要发现
- 门冬胰岛素和赖脯胰岛素较常规胰岛素达餐后目标且低血糖更少,胎儿结局相似。
- 甘精胰岛素和地特胰岛素与NPH相比母婴结局相似且似乎安全。
- 二甲双胍疗效好且有短期安全性数据,但可自由穿过胎盘且缺乏长期安全性数据。
- 格列本脲疗效好且有短期数据,但穿过胎盘,与胰岛素相比可能增加大于胎龄儿和新生儿低血糖发生率。
关键数值与推荐
- GDM初始管理包括强化生活方式调整,常需行为与营养改变以优化血糖控制。
- 当血糖目标未达到时启动GDM药物治疗。
临床怎么用
- GDM血糖不达标时优先考虑胰岛素治疗。
- 选择速效胰岛素类似物门冬或赖脯胰岛素以减少低血糖。
- 长效胰岛素类似物甘精或地特胰岛素可作为NPH的替代。
- 口服降糖药可作替代但需权衡胎盘通过和长期安全性不确定性。
局限性
- 二甲双胍缺乏长期安全性数据。
- 格列本脲与大于胎龄儿和新生儿低血糖风险相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gestational diabetes mellitus (GDM) is associated with an increased risk of adverse pregnancy outcomes in the setting of poor glycemic control. The initial management for GDM includes intensive lifestyle modification, which often requires behavioral and nutritional changes to optimize glycemic control. Pharmacotherapy for GDM is initiated when glycemic targets are not met. The rapid-acting bolus analogues aspart and lispro achieve postprandial targets with less hypoglycemia compared to regular insulin, with similar fetal outcomes. The long-acting insulin analogues glargine and detemir appear safe with similar maternal/fetal outcomes compared to NPH. While insulin has been the mainstay therapy for women with GDM to improve glycemic control when lifestyle modifications are insufficient, certain oral antihyperglycemic drugs (OADs) can be considered as alternative treatment options for GDM but continue to be controversial for use as first-line treatment options compared to insulin by many professional bodies. Metformin has good efficacy and short-term safety data but it freely crosses the placenta and long-term safety data are lacking. Glyburide has good efficacy and short-term data but it also crosses the placenta and may be associated with increased rates of large-for-gestational-age (LGA) infants and neonatal hypoglycaemia when compared with insulin. This review aims to give an overview of the pharmacological treatment for women with GDM including some of the known safety profiles of current therapeutic options.
引用
- Mukerji G, Feig DS. Pharmacological Management of Gestational Diabetes Mellitus. Drugs. 2017. PMID: 28864965. doi:10.1007/s40265-017-0807-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。